Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZM0414 in R/R Multiple Myeloma and DLBCL
NCT05121103Phase 1Terminated
- Sponsor
- Epizyme, Inc.
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ezm0414 in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL), sponsored by Epizyme, Inc. Primary endpoints: Treatment-Emergent Adverse Events up to 87 days, Dose-limiting Toxicities and 1 more. Started May 2022; status: terminated.
02
Drugs
ezm0414
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05121103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121103.